Life Sciences Consulting

Life Sciences Consulting

Life Sciences Consulting

For more than 25 years, life science companies, law firms, and regulatory agencies around the globe have turned to CRA's life sciences consultants when they need clarity and solutions to the industry’s most complex issues. Clients value our deep industry knowledge, rigorous analytic techniques, and decades of hands-on experience spanning thousands of successful engagements.

Clients rely on CRA’s objective point of view and innovative insights when they want a new way to look at their most complex problems. More than 90% of our clients are repeat clients. For 25 years, our global team of senior experts has helped life sciences companies anticipate trends and break through strategic barriers.

Comprehensive strategic expertise

We help clients address challenges in four key areas of strategy.

 
Asset
Portfolio
Corporate
 
 
 
 
Achieve pricing and market access goals
Drive returns across
the portfolio
Demonstrate value to wider stakeholders
 
 
 
 
Maximize launch
impact
Optimize portfolio performance
Adapt the business model
 
 
 
 
Ensure robust
evidence generation
Focus development programs
Improve R&D performance
 
 
 
 
Prioritize investment decisions
Shape portfolio
strategy
Drive company
growth

What makes us different

A client-focused approach is in our DNA.

Collaborative
hands-on senior leadership
Experienced
guidance
Rigorous
analytics
Objective
balanced recommendations
Tailored
approaches
Practical
actionable solutions

Our advantage

Our dedicated expert teams and institutional knowledge lead to deeper insights and better decisions.


Market Research
  • 10+ experienced team members dedicated to stakeholder insights to leverage best-in-class research methodologies
  • Experienced in ensuring accurate and insightful data capture across stakeholders and regions
  • Led by highly innovative expert researchers who provide oversight and design input to all projects, and leverage best practices from hundreds of engagements every year

Advanced Analytics
  • 25+ team members entirely focused on advanced analytics within pharma
  • Innovative approaches built over 10+ years in the space
  • Integration across consulting teams to maximize effectiveness
  • Secondary data capabilities are source agnostic and delivered by a dedicated team of analytics experts skilled in extracting unique insights for evidence-based decision making around product launches

Healthcare Products
  • Pharmaceuticals
  • Biologics
  • Diagnostics
  • Medical devices
  • Consumer health

Therapy Area Strategy

When clients need to develop and implement superior product launch and lifecycle strategies across a variety of therapeutic areas, they turn to CRA.

Analgesia
Anti-infectives
Cardiovascular
Central nervous system
Dermatology
Endocrinology
Gastrointestinal
Immunology
Inflammation
Oncology
Neuroscience
Nutrition
Rare diseases
Urology
Vaccines

Healthcare Policy
  • 10+ experienced team members
  • Policy analysis backed by independence, rigor, and 15 years of experience
  • Influencing the macro policy environment
  • Anticipating changes in the policy environment
  • Developing policy positioning – assessing and comparing policy options across different markets
  • Aligning policy processes with commercial priorities

Our life sciences practice is made up of 185 consultants that blend decades of global business experience with an extensive understanding of life sciences.

Meet our senior team >

Sample engagements

We help clients answer their toughest strategic issues.

  • Global launch for new drug
    CRA helped our client defend their franchise and develop a global launch strategy with individually defined work streams and global launch governance plan.

  • Global launch for new drug
    We developed a global strategy that addressed market access hurdles, provided tactical plans for each market, and aligned internal stakeholders to support market access.

  • Biosimilar risk mitigation strategy
    Our experts prepared a global strategy our client could use to understand the biosimilar landscape, defend themselves, launch biosimilars and prepare for the entry of new biosimilars.

<    >

CRA’s policy team provides analysis and insights into issues affecting the life sciences industry. We work across global, regional and national policy areas to assess and make recommendations relating to current situations and the potential impacts of proposed policy changes, in support of clients’ strategic priorities.

CRA has a reputation for independence and rigour, benefiting from long standing relationships with most leading pharma organisations as well as national governments and the European Commission and industry associations such as IFPMA, EFPIA, and PhRMA. Our specialist team has provided unique policy oversight for the past 15 years, working closely with our strategy consultants to support clients in achieving their wider corporate objectives. We deliver high quality, robust analysis but in a compelling fashion that is accessible to the target audience, whomever it may be.

Clients come to CRA’s policy team when they want to:

  • Evaluate the impact of regulation and how clients can optimise their position accordingly
  • Anticipating future changes in the policy environment and the business implications  associated with them
  • Develop policy positioning - assessing the cost and benefits of different policy options
  • Support government affairs functions in managing and coordinating global policy processes in alignment with commercial priorities of the business
  • Influence the macro policy environment at global, regional, and national level through robust evidence development

Specialist policy capabilities

National and market
related policy issues

Healthcare financing and international health policies

  • Health Technology Assessment
  • Innovative contracting options
  • Rare diseases and orphan drugs policies
  • Competitive tendering for pharmaceuticals
  • Pricing policies (reference pricing, differential pricing)
  • R&D policies and the innovation value chain
  • Models of healthcare financing
  • Impact of Universal Health Coverage
  • Access to medicines in low and middle income countries
  • International trade agreements
  • Evolution of regulatory trends

Our life sciences practice is made up of 185 consultants that blend decades of global business experience with an extensive understanding of life sciences.

Meet our senior team >

Sample engagements

  • Policy analysis – A global pharma company sought insight into the policy implications of variations in access to Multiple Sclerosis treatments across Europe. CRA’s analysis and report has helped the company build its argumentation to policy makers around barriers to effective MS treatment.

  • HTA impact analysis – EFPIA & PhRMA asked CRA to describe how HTA systems are evolving and their impact on access to medicines in a range of markets. The study demonstrated that HTAs are increasingly delivered in a more timely fashion but are not enabling earlier access to innovative medicines.

  • Reimbursement policy – CRA reviewed reimbursement of orphan medicines across Europe for a pharma company supplying therapies in this sector. A toolkit on reimbursement practices at national, regional and local levels, set out best and worst practices and their consequences, to support argumentation with payers.

<    >

CRA’s life sciences litigation support is grounded in a comprehensive understanding of pharmaceutical, biotechnology, medical device, and diagnostic markets. For more than 30 years, our experts have consulted with major life science companies, law firms, and regulatory agencies around the globe, providing the industry experience and analytical expertise needed to solve their most challenging strategic problems and resolve their most contentious disputes.

CRA has a reputation for delivering rigorous analysis and expert testimony that meets the highest standards. Our witnesses are respected for their professional excellence and effectiveness in highly demanding life sciences cases. Our team members have extensive business consulting and litigation experience in the life sciences industries. The academic backgrounds of our consultants are complemented by results-focused, practical experience. This combination allows CRA to apply effective expert testimony and non-testifying expertise to our clients’ most important problems.

Client challenges

Litigation

Regulatory agency proceedings

Arbitration

  • Antitrust
  • Commercial disputes
  • Intellectual property
  • Government investigations
  • Canadian Ministry of Health
  • US Federal Trade Commission
  • European Commission
  • UK Office of Fair Trading
  • ICC
  • ICSID
  • LCIA
  • UNCITRAL

Disputes involving

  • Antitrust, including reverse payments and delayed generic entry
  • Class certification
  • Commercially reasonable efforts
  • Damages assessment
  • Economic fraud
  • Government investigations
  • Intellectual property disputes and valuations
  • International arbitrations
  • Off-label marketing and product liability
  • Pricing, reimbursement, and distribution
  • Transfer pricing policy
  • Labor and employment

Our consultants blend decades of global business experience with an extensive understanding of life sciences.

Meet our senior team >

Sample engagements

  • A global pharma company abandoned a product launch following unfavorable clinical trial results. When their stock price fell, they were sued for allegedly concealing information. The court accepted our analysis/conclusion that information concealment was an unlikely reason for the price change.

  • In a matter involving an antitrust counterclaim, a generic pharmaceutical manufacturer alleged that a blockbuster brand manufacturer attempted to monopolize the market and delay entry of the generic product. A CRA expert analyzed market definition, competitive effects, and lost profits damages estimates. The matter settled favorably for our client shortly before trial.

<    >